Medium Cut-Off (MCO) membranes reduce inflammation in chronic dialysis patients - A randomized controlled clinical trial

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Zickler, Daniel ^a   Schindler, Ralf ^a   Willy, Kevin ^a   Martus, Peter ^b   Pawlak, Michael ^c   Storr, Markus ^d   Hulko, Michael ^d   Boehler, Torsten ^d   Glomb, Marcus A ^e   Liehr, Kristin ^e   Henning, Christian ^e   Templin, Markus ^c   Trojanowicz, Bogusz ^e   Ulrich, Christof ^e   Werner, Kristin ^d   Fiedler, Roman ^e   Girndt, Matthias ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NMI Technologietransfer GmbH   (Germany)

^d Gambro Dialysatoren GmbH   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INTERLEUKIN 6; MESSENGER RNA; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; ARTIFICIAL MEMBRANE; BETA 2 MICROGLOBULIN; CYTOKINE;

ADULT; ADVERSE OUTCOME; ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL KIDNEY; C REACTIVE PROTEIN BLOOD LEVEL; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSIS MEMBRANE; FEMALE; GENE EXPRESSION; HEMODIALYSIS PATIENT; HIGH FLUX DIALYZER; HUMAN; HUMAN CELL; IL 6 GENE; INTERLEUKIN 6 BLOOD LEVEL; MALE; MEDICAL DEVICE COMPLICATION; MEDIUM CUT OFF MEMBRANE; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RNA STABILITY; TNF ALPHA GENE; TREATMENT DURATION; TUMOR NECROSIS FACTOR BLOOD LEVEL; ADVERSE EFFECTS; ARTIFICIAL MEMBRANE; CLINICAL TRIAL; COMPLICATION; HEMODIALYSIS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

BETA 2-MICROGLOBULIN; CROSS-OVER STUDIES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; RENAL DIALYSIS;

EID: 85009286665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169024     Document Type: Article

References (27)

1. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012; 23(7):1258-70. PubMed Central PMCID: PMC3380651. doi: 10.1681/ASN.2011121175 PMID: 22626821
2. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney international. 2003; 63(5):1934-43. doi: 10.1046/j.1523-1755.2003.00924.x PMID: 12675874
3. Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney international. 2012; 82(12):1297-303. doi: 10.1038/ki.2012.301 PMID: 22895515
4. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. The New England journal of medicine. 2002; 347(25):2010-9. doi: 10.1056/NEJMoa021583 PMID: 12490682
5. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al. Effect of membrane permeability on survival of hemodialysis patients. Journal of the American Society of Nephrology: JASN. 2009; 20(3):645-54. PubMed Central PMCID: PMC2653681. doi: 10.1681/ASN.2008060590 PMID: 19092122
6. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2009; 24(2):562-70.
7. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013; 28(1):192-202. doi: 10.1093/ndt/gfs407 PMID: 23229932
8. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Carreras J, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. Journal of the American Society of Nephrology: JASN. 2013; 24(3):487-97. PubMed Central PMCID: PMC3582206. doi: 10.1681/ASN.2012080875 PMID: 23411788
9. Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. Journal of the American Society of Nephrology: JASN. 2012; 23(6):1087-96. PubMed Central PMCID: PMC3358764. doi: 10.1681/ASN.2011121140 PMID: 22539829
10. Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. Int J Artif Organs. 2013; 36(7):455-63. doi: 10.5301/ijao.5000220 PMID: 23661558
11. Girndt M, Fiedler R, Martus P, Pawlak M, Storr M, Boehler T, et al. High cut-off dialysis in chronic hemodialysis patients. Eur J Clin Invest. 2015.
12. Zickler D, Willy K, Girndt M, Fiedler R, Martus P, Storr M, et al. High cut-off dialysis in chronic haemodialysis patients reduces serum procalcific activity. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2016.
13. Kneis C, Beck W, Boenisch O, Klefisch F, Deppisch R, Zickler D, et al. Elimination of middle-sized uremic solutes with high-flux and high-cut-off membranes: a randomized in vivo study. Blood purification. 2013; 36(3-4):287-94. doi: 10.1159/000356224 PMID: 24496201
14. Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. MCO Membranes: Enhanced Selectivity in High-Flux Class. Scientific reports. 2015; 5:18448. PubMed Central PMCID: PMC4680880. doi: 10.1038/ srep18448 PMID: 26669756
15. Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2016.
16. Hsu HY, Wittemann S, Schneider EM, Weiss M, Joos TO. Suspension microarrays for the identification of the response patterns in hyperinflammatory diseases. Medical engineering & physics. 2008; 30(8):976-83.
17. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC nephrology. 2008; 9:11. PubMed Central PMCID: PMC2564915. doi: 10.1186/1471-2369-9-11 PMID: 18808676
18. Keir R, Evans ND, Hutchison CA, Vigano MR, Stella A, Fabbrini P, et al. Kinetic modelling of haemodialysis removal of myoglobin in rhabdomyolysis patients. Computer methods and programs in biomedicine. 2014; 114(3):e29-38. doi: 10.1016/j.cmpb.2013.07.017 PMID: 24008249
19. Krieter DH, Devine E, Wanner C, Storr M, Krause B, Lemke HD. Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. Artificial organs. 2014; 38(10):888-93. doi: 10.1111/aor.12248 PMID: 24392952
20. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 2000; 102(21):2636-42. PMID: 11085968
21. Al-Aly Z. Arterial calcification: a tumor necrosis factor-alpha mediated vascular Wnt-opathy. Translational research: the journal of laboratory and clinical medicine. 2008; 151(5):233-9.
22. Lu P, Liu J, Pang X. Pravastatin inhibits fibrinogen- and FDP-induced inflammatory response via reducing the production of IL-6, TNF-alpha and iNOS in vascular smooth muscle cells. Mol Med Rep. 2015; 12(4):6145-51. doi: 10.3892/mmr.2015.4149 PMID: 26238934
23. Neirynck N, Glorieux G, Schepers E, Verbeke F, Vanholder R. Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: a prospective cohort study. PloS one. 2015; 10(3):e0122073. PubMed Central PMCID: PMC4379033. doi: 10.1371/journal.pone.0122073 PMID: 25823004
24. Talmud PJ, Holmes MV. Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2015; 35(11):2281-9. doi: 10.1161/ATVBAHA.115.305234 PMID: 26338298
25. Karabina S, Ninio E. Plasma PAFAH/PLA2G7 Genetic Variability, Cardiovascular Disease, and Clinical Trials. Enzymes. 2015; 38:145-55. doi: 10.1016/bs.enz.2015.09.002 PMID: 26612651
26. Katan M, Moon YP, Paik MC, Wolfert RL, Sacco RL, Elkind MS. Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study. PLoS One. 2014; 9(1): e83393. PubMed Central PMCID: PMC3886969. doi: 10.1371/journal.pone.0083393 PMID: 24416164
27. Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Morgera S, et al. Beta2-microglobulin removal and plasma albumin levels with high cut-off hemodialysis. Int J Artif Organs. 2007; 30(5):385-92. PMID: 17551901